CymaBay Therapeutics Inc. (CBAY) financial statements (2022 and earlier)

Company profile

Business Address 7575 GATEWAY BOULEVARD
NEWARK, CA 94560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:194,600146,300 178,70097,20017,000
Cash and cash equivalents125,80628,193 48,99523,05410,495
Short-term investments60,729118,130 129,66974,1569,400
Other undisclosed cash, cash equivalents, and short-term investments8,065(23) 36(10)(2,895)
Receivables    5,000 
Prepaid expense2,1932,764 2,5941,2081,369
Other current assets   304126165
Other undisclosed current assets(5,694)2,521 (36)10(6)
Total current assets:191,099151,585 181,562103,54418,528
Noncurrent Assets
Operating lease, right-of-use asset254272 
Property, plant and equipment1,1781,761 2,9056977
Long-term investments and receivables8,067     
Long-term investments8,067     
Other noncurrent assets1,720207 2,280634754
Total noncurrent assets:11,2192,240 5,185703831
TOTAL ASSETS:202,318153,825 186,747104,24719,359
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,6008,910 5,8277,1115,466
Accounts payable2,728231 1,9731,311899
Accrued liabilities5,8864,910 3,8545,7574,501
Employee-related liabilities3,9863,769    
Interest and dividends payable    4366
Debt    3,1082,700
Restructuring reserve 18    
Other undisclosed current liabilities5,766929 8,5886,0911,145
Total current liabilities:18,3669,857 14,41516,3109,311
Noncurrent Liabilities
Long-term debt and lease obligation6951,262  2,9906,098
Long-term debt, excluding current maturities    2,9906,098
Operating lease, liability6951,262 
Liabilities, other than long-term debt   1,914 13
Deferred rent credit   1,914
Other liabilities     13
Other undisclosed noncurrent liabilities49,625(1,262)    
Total noncurrent liabilities:51,0151,262 1,9142,9906,111
Total liabilities:69,38111,119 16,32919,30015,422
Stockholders' equity
Stockholders' equity attributable to parent132,937142,706 170,41884,9473,937
Common stock87 642
Additional paid in capital899,798819,549 693,534535,503426,895
Accumulated other comprehensive income (loss)(13)8 (58)(44)(1)
Accumulated deficit(766,856)(676,858) (523,064)(450,516)(422,959)
Total stockholders' equity:132,937142,706 170,41884,9473,937
TOTAL LIABILITIES AND EQUITY:202,318153,825 186,747104,24719,359

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues
(Revenue, Net)
    10,000 
Gross profit:    10,000 
Operating expenses(87,582)(52,602) (72,505)(31,325)(25,586)
Operating loss:(87,582)(52,602) (72,505)(21,325)(25,586)
Nonoperating income (expense)(2,416)1,616 (43)(5,152)252
Investment income, nonoperating1671,616 3,988621176
Other nonoperating income (expense)   (3,288)(5,773)76
Interest and debt expense(2,895)  (407)(1,080)(1,337)
Loss before gain (loss) on sale of properties:(92,893)(50,986) (72,955)(27,557)(26,671)
Other undisclosed net income2,895  407  
Net loss available to common stockholders, basic:(89,998)(50,986) (72,548)(27,557)(26,671)
Dilutive securities, effect on basic earnings per share   (422)  
Net loss available to common stockholders, diluted:(89,998)(50,986) (72,970)(27,557)(26,671)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(89,998)(50,986) (72,548)(27,557)(26,671)
Other comprehensive income (loss)(21)(72) (14)(43)20
Comprehensive loss, net of tax, attributable to parent:(90,019)(51,058) (72,562)(27,600)(26,651)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: